

Pfizer Support to European and International Patient Organisations in 2014

Support to European organisations

The below list contains information on the support Pfizer has provided to European-level patient organisations in 2014, and services contracted from them (e.g. speaker fees), and to national and global patient organisations for European-level work. It follows the standards set out in the EFPIA code of practice governing relationships between the pharmaceutical industry and patient associations. Note that many of these declarations have also been declared in the country in which an organisation is based, dependent on local guidelines.

Alzheimer Europe					
<p>Organisation Description Alzheimer Europe is a non-governmental organisation aimed at raising awareness of all forms of dementia by creating a common European platform through co-ordination and co-operation between Alzheimer organizations throughout Europe. Alzheimer Europe is also a source of information on all aspects of dementia.</p> <p>Funding €10,000</p> <p>Funding Description Bronze sponsorship of the public affairs activities of Alzheimer Europe.</p> <p>This information is also declared on www.pfizer.be. Please be aware that the format may differ to follow Belgian transparency guidelines.</p>					
AntiCoagulation Europe (ACE)					
<p>Organisation Description ACE is a UK registered charity founded in the year 2000. ACE works with patients, healthcare professionals, NHS trusts, Industry, Governments, other charities and patient groups and a wide range of other organisations. Its aims are: the prevention of thrombosis; the provision of information, education and support; the promotion of independence - supporting people to take an active part in their own healthcare.</p> <p>Funding</p> <table border="1"> <tr> <td>£9,750</td> <td>The BMS-Pfizer Alliance (an alliance between Bristol-Myers Squibb Pharmaceuticals Ltd and Pfizer Ltd) made a donation towards the costs of Anticoagulation Europe’s regional patient education meetings. This figure is the total of Pfizer’s contribution via the Pfizer-BMS alliance, and is 50% of the total paid.</td> </tr> <tr> <td>£162.50</td> <td>The BMS-Pfizer Alliance paid for two delegate places at the Anticoagulation in Practice meeting for healthcare professionals, which is organised by Anticoagulation Europe. This figure is the total of Pfizer’s contribution via the Pfizer-BMS alliance, and is 50% of the total paid.</td> </tr> </table> <p>This information is also declared on www.pfizer.co.uk. Please be aware that the format may differ to follow UK transparency guidelines.</p>		£9,750	The BMS-Pfizer Alliance (an alliance between Bristol-Myers Squibb Pharmaceuticals Ltd and Pfizer Ltd) made a donation towards the costs of Anticoagulation Europe’s regional patient education meetings. This figure is the total of Pfizer’s contribution via the Pfizer-BMS alliance, and is 50% of the total paid.	£162.50	The BMS-Pfizer Alliance paid for two delegate places at the Anticoagulation in Practice meeting for healthcare professionals, which is organised by Anticoagulation Europe. This figure is the total of Pfizer’s contribution via the Pfizer-BMS alliance, and is 50% of the total paid.
£9,750	The BMS-Pfizer Alliance (an alliance between Bristol-Myers Squibb Pharmaceuticals Ltd and Pfizer Ltd) made a donation towards the costs of Anticoagulation Europe’s regional patient education meetings. This figure is the total of Pfizer’s contribution via the Pfizer-BMS alliance, and is 50% of the total paid.				
£162.50	The BMS-Pfizer Alliance paid for two delegate places at the Anticoagulation in Practice meeting for healthcare professionals, which is organised by Anticoagulation Europe. This figure is the total of Pfizer’s contribution via the Pfizer-BMS alliance, and is 50% of the total paid.				
Arrhythmia Alliance					

Organisation Description

Arrhythmia Alliance (A-A) is a UK-based coalition of charities, patient groups, patients, carers, medical groups and allied professionals. These groups remain independent, however, working together under the A-A umbrella to promote timely and effective diagnosis and treatment of arrhythmias.

Funding

€67,5000

Funding Description

Corporate sponsorship for the launch and dissemination of the Route Map for Change.

This information is also declared on www.pfizer.co.uk. Please be aware that the format may differ to follow UK transparency guidelines.

Atrial Fibrillation Association (AFA)**Organisation Description**

The Atrial Fibrillation Association (AFA) is a UK registered charity which focuses on raising awareness of Atrial Fibrillation (AF) by providing information and support materials for patients and medical professionals involved in detecting, diagnosing and managing Atrial Fibrillation.

Contracted services

£215	The BMS-Pfizer Alliance paid an honorarium for the participation of an AF Association staff member in a BMS-Pfizer Alliance European Advisory Board meeting which took place in the UK. This figure is the total of Pfizer's contribution via the Pfizer-BMS alliance, and is 50% of the total paid.
£215	The BMS-Pfizer Alliance paid an honorarium for the participation of an AF Association staff member in a BMS-Pfizer Alliance European Advisory Board meeting which took place in the UK. This figure is the total of Pfizer's contribution via the Pfizer-BMS alliance, and is 50% of the total paid.
£215	The BMS-Pfizer Alliance paid an honorarium for the participation of an AF Association staff member in a BMS-Pfizer Alliance European Advisory Board meeting which took place in the UK. This figure is the total of Pfizer's contribution via the Pfizer-BMS alliance, and is 50% of the total paid.
£215	The BMS-Pfizer Alliance paid an honorarium for the participation of an AF Association staff member in a BMS-Pfizer Alliance European Advisory Board meeting which took place in Europe but outside the UK. This figure is the total of Pfizer's contribution via the Pfizer-BMS alliance, and is 50% of the total paid.
£690	The BMS-Pfizer Alliance paid an honorarium for preparation time and participation of an AF Association staff member in a BMS-Pfizer Alliance Patient Group Summit which took place in Europe but outside the UK. This figure is the total of Pfizer's contribution via the Pfizer-BMS alliance, and is 50% of the total paid.
Expenses	The BMS-Pfizer Alliance paid expenses for one AF Association staff member in relation to their participation in a BMS-Pfizer Alliance Patient Group Summit which took place in Europe: Flights = £188.50 / Accommodation = £44.50 / Transfers = £45.14. This figure is the total of Pfizer's contribution via the Pfizer-BMS alliance, and is 50% of the total paid.

This information is also declared on www.pfizer.co.uk. Please be aware that the format may differ

to follow UK transparency guidelines.

Europa Donna

Organisation Description

Europa Donna, the European Breast Cancer Coalition, is an independent non-profit organisation founded in 1993, whose members are affiliated groups from countries across Europe. The Coalition works to raise awareness of breast cancer and to mobilise the support of European women in pressing for improved breast cancer education, appropriate screening, optimal treatment and care and increased funding for research. Europa Donna represents the interests of European women regarding breast cancer to local and national authorities, as well as to institutions of the EU. Europa Donna has 46 country members and its Head Office is located in Milan, Italy.

Funding

€50,000

Funding Description

Pfizer Inc provided support for the Advocacy Leader Conference 2014, the European Breast Cancer Conference 2014, the European Breast Cancer Advocacy Training Course, Breast Health Day 2014, publications, European Parliament Information Sessions, Europe-wide breast cancer advocacy presence, Europa Donna 20th Anniversary Activities, Forum Support, and advocacy for women with metastatic breast cancer.

This information is also declared on www.pfizer.it. Please be aware that the format may differ to follow Italian transparency guidelines.

European Cancer Patient Coalition

Organisation Description

Established in 2003, the European Cancer Patient Coalition is the voice of the European cancer patient community, uniquely representing the interests of all cancer patient groups from the most common to the rarest forms of cancer.

Funding

€20,000	Pfizer Inc provided sponsorship of ECPC's European cancer equality project.
\$18,000	Pfizer Inc provided sponsorship of ECPC's General Assembly.

This information is also declared on www.pfizer.be. Please be aware that the format may differ to follow Belgian transparency guidelines.

European Federation of Neurological Associations (EFNA)

Organisation Description

The European Federation of Neurological Associations (EFNA) brings together European umbrella organisations of neurological patient advocacy groups, to work with other associations in the field of neurology, in what has been termed a 'Partnership for Progress'. EFNA engages in activities, which contribute to the advancement of neurology and related areas with a view to improving the quality of life of people living with neurological conditions, their families and carers.

Funding

€10,000	Pfizer Inc provided support to EFNA's EU-level advocacy activities.
\$18,000	Pfizer Inc provided support to EFNA's advocacy on Brain, Mind & Pain disorders.

This information is also declared on www.pfizer.be. Please be aware that the format may differ to follow Belgian transparency guidelines.

European Haemophilia Consortium (EHC)

Organisation Description

The European Haemophilia Consortium (EHC) is a European patient group representing national member organisations from 43 countries in Europe including members in all 28 Member States. The EHC is working to reduce the burden of the disease on both the individual and on society. Its mission is to improve the quality of life of people with Haemophilia in Europe.

Funding

€67,000

Funding description

Pfizer Inc provided support to EHC's HTA workshop.

This information is also declared on www.pfizer.be. Please be aware that the format may differ to follow Belgian transparency guidelines.

European Men's Health Forum (EMHF)

Organisation Description

The European Men's Health Forum (EMHF) is the only European organisation dedicated to the improvement of men's health in all its aspects, and a platform for the collaboration of a wide range of stakeholder groups in Europe. It aims to promote collaboration between interested individuals and organisations on the development and application of health policies, research, education and prevention programmes. In addition, EMHF strives to raise the profile of men's health issues across Europe, develop Europe-wide policies and support the establishment and development of men's health organisations that pursue similar objectives in each European country.

Funding

\$35,000

Funding Description

Pfizer Inc provided support to EMHF's ongoing series of roundtables to improve men's use of primary care services across Europe.

This information is also declared on www.pfizer.be. Please be aware that the format may differ to follow Belgian transparency guidelines.

European Patients' Forum (EPF)

Organisation Description

The European Patients' Forum (EPF) is the umbrella patients' organisation at EU level. It brings together a broad range of leading European and national patients' organisations in different disease areas. Representing over 150 million patients, the EPF is a key interlocutor with European institutions, and promotes patients' rights, participation and involvement in EU healthcare

developments.

Funding

€20,000	Pfizer Service Company provided core funding to EPF.
€10,000	Pfizer Romania provided funding for EPF's Capacity Building Programme.
€10,000	Pfizer Inc provided funding for EPF's Capacity Building Programme.

This information is also declared on www.pfizer.be. Please be aware that the format may differ to follow Belgian & Luxembourgish transparency guidelines.

EURORDIS (European Organisation for Rare Diseases)

Organisation Description

EURORDIS is a patient-driven alliance of patient organisations and individuals active in the field of rare diseases. EURORDIS' mission is to build a strong pan-European community of patient organisations and people living with rare diseases, to be their voice at the European level, and - directly or indirectly - to fight against the impact of rare diseases on their lives.

Funding

€25,000	Pfizer International Operations provided support to EURORDIS' Round Table of Companies (ERTC)
€25,000	Pfizer International Operations provided annual support to EURORDIS' work programme
€10,000	Pfizer Inc provided support to EURORDIS' membership meeting

This information is also declared on www.pfizer.fr. Please be aware that the format may differ to follow French transparency rules.

Lung Cancer Europe (LuCE)

Organisation Description

Lung Cancer Europe is a non-governmental organisation which was established in 2013 to provide a voice for lung cancer patients and their families at a European level. Through its member organisations (which are lung cancer organisations with a patient focus), LuCE reflects patients' and their carers' and families' unique and direct experience and expertise in healthcare. LuCE is based in Switzerland.

Funding

€29,160

Funding Description

Pfizer Pharma GmbH provided support to LuCE's annual work programme 2014.

Sarcoma Patients EuroNet (SPAEN)

Organisation Description

Established in 2009, Sarcoma Patients EuroNet e.V./Assoc. (SPAEN) is a collaborative association based in Germany, which brings together European advocacy and support groups working together with patients who have some of the rarest cancers. Acting in partnership with clinical experts, scientific researchers and other stakeholders SPAEN is working to improve the treatment and care of sarcoma patients in Europe through improving information and support, and by increasing the awareness of sarcoma in the medical landscape and amongst the general public.

Funding
€25,000

Funding Description

Pfizer Inc provided annual support to SPAEN for 2014.

Support to global organisations based in Europe

The below list contains information on the support Pfizer has provided to global patient organisations in 2013 based in Europe.

CML Advocates Network					
<p>Organisation Description The CML Advocates Network is a worldwide network of non-profit organisations supporting patients with Chronic Myeloid Leukemia (CML) and their relatives. The network does this by sharing knowledge and best practice, running joint campaigns, and educating advocates how to build and grow patient organisations. The network is run by volunteers who are CML patients. The CML Advocates Network is formally hosted by the Leukemia Patient Advocates Foundation, a global patient-led non-profit foundation registered in Switzerland.</p>					
<p>Funding €50,000</p>					
<p>Funding Description Pfizer Inc provided support for the annual CML Horizons meeting.</p>					
Global Lung Cancer Coalition					
<p>Organisation Description The GLCC is an umbrella organisation that supports lung cancer awareness and best practice sharing among patient groups internationally. The GLCC operates from the UK.</p>					
<p>Funding £30,000</p>					
<p>Funding description Pfizer Inc provided funding to support the annual work programme of GLCC.</p>					
<p>This information is also declared on www.pfizer.co.uk. Please be aware that the format may differ to follow UK transparency guidelines.</p>					
International Alliance of Patients’ Organisations (IAPO)					
<p>Organisation Description IAPO is a unique global alliance representing patients of all nationalities across all disease areas and promoting patient-centred healthcare around the world. IAPO is registered in the Netherlands.</p>					
<p>Funding</p> <table border="1"> <tr> <td>\$50,000</td> <td>Pfizer Inc provided support to IAPO as a Health Industry Partner in 2014.</td> </tr> <tr> <td>\$20,000</td> <td>Pfizer Inc provided support to IAPO’s Latin American regional meeting programme.</td> </tr> </table>		\$50,000	Pfizer Inc provided support to IAPO as a Health Industry Partner in 2014.	\$20,000	Pfizer Inc provided support to IAPO’s Latin American regional meeting programme.
\$50,000	Pfizer Inc provided support to IAPO as a Health Industry Partner in 2014.				
\$20,000	Pfizer Inc provided support to IAPO’s Latin American regional meeting programme.				
<p>This information is also declared on www.pfizer.co.uk. Please be aware that the format may differ to follow UK transparency guidelines.</p>					
International Federation of Psoriasis Organisations (IFPA)					

Organisation Description

IFPA is a non-profit organization made up of psoriasis associations from around the world. IFPA unites psoriasis associations so that their global campaign for improved medical care, greater public understanding and increased research will improve the lives of people who live with psoriasis and psoriatic arthritis and explore the challenges psoriasis presents to the international psoriasis community. IFPA is based in Sweden.

Funding

€65,000

Funding Description

Pfizer Inc provided funding to IFPA at the second tier membership level.

International Kidney Cancer Coalition (IKCC)**Organisation Description**

IKCC is an independent and democratic network of patient support and advocacy organizations established with the mission of improving the quality of life of patients and their families living with kidney cancer. IKCC provides information, support and assistance to national kidney cancer organizations. Management services for IKCC are provided by Das Wissenhaus GmbH, a service provider for scientific and medical information & communication and acts in the world of medicine/oncology/science (experts, researchers, clinics, patients, patient-organizations, media, companies etc.).

Funding

\$42,000

Funding Description

Pfizer Inc provided support for International Conference of Kidney Cancer Patient Advocates.

Appendix: Funding to organisations engaged in some work with patients.

Pfizer provides funding to a number of organisations that are not patient organisations, but which have patient organisation membership or are otherwise relevant to patients. As such, they are listed here for the sake of transparency.

European Alliance for Personalised Medicine (EAPM): Founded in 2012, EAPM brings together Europe's leading healthcare experts, healthcare organisations and institutions, and patient advocates to improve patient care by accelerating the development, delivery and uptake of personalised healthcare including personalised medicine and diagnostics. In 2014, Pfizer Inc provided EAPM with €25,000 to support its annual work programme.

European Brain Council (EBC): The European Brain Council (EBC) is a coordinating council formed by European organisations in neurology, neurosurgery, psychiatry, basic brain research (neuroscience), as well as patient organisations and companies from within the pharma and biotech industries. It represents a vast network of patients, doctors and scientists, and these stakeholders along with its industrial partners make it eminently suited to work in close partnership with the European Parliament and Commission, national governments as well as other policy making bodies. In 2014, Pfizer Ltd provided a donation of £50,000 for scientific and policy events on stroke prevention in atrial fibrillation, and Pfizer Inc provide €50,000 to cover membership fees from 2013 to 2015.

Pain Alliance Europe (PAE): PAE is a multi-stakeholder alliance that aims to improve the quality of life of people living with chronic pain in Europe, by promoting awareness of chronic pain and promoting a European policy on chronic pain, in order to reduce the impact of chronic pain on all areas of European society. Pfizer Inc provided PAE with €15,000 to support chronic pain awareness activities.

Rare Cancers Europe: RCE is a partnership of cooperating organisations that work together to place the issue of rare cancers firmly on the European policy agenda, to identify and promote appropriate solutions and to exchange best practice. RCE is administered by the European Society for Medical Oncology (ESMO) based in Switzerland. In 2014, Pfizer Pharma GmbH provided €50,000 in membership fees to RCE.